1. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes

2. Program

3. Basal Insulin 101

4. Antihyperglycemic Therapy in Adults With T2D

5. Antihyperglycemic Therapy in Adults With T2D (cont)

6. Drug-Specific and Individual Factors to Consider

7. Pharmacokinetic Profile of Currently Available Single Insulin Products

8. Ultra-Long-Acting Insulins Potential Benefits in T2D

9. Basal Insulin Initiation in People With T2D

10. U-300 Insulin Glargine Determining Starting Dose (and Dose Conversion) in T2D

11. Insulin Glargine U-100 vs U-300 in People With T2D Meta-Analysis of 3 Phase 3 Studies

12. Flexible vs Fixed Dosing U-300 Glargine Sub-Studies of Phase 3 Studies

13. Insulin Degludec Determining Starting Dose (and Dose Conversion) in T2D

14. Insulin Degludec Hypoglycemia

15. Flexible vs Fixed Dosing of Insulin Degludec

16. Ultra-Long-Acting Insulin Comparison

17. Who May Benefit From Ultra-Long-Acting Insulins?

18. Reasons for Switching Insulin Products

19. Overcoming Insulin-Related Barriers Like a Pro

20. Barriers to Insulin Initiation Persons Living With Diabetes

21. Barriers to Insulin Initiation Clinicians

22. Strategies to Overcome Barriers Persons Living With Diabetes

23. Education in Insulin Initiation Insulin Delivery

24. Overcoming Barriers in Clinicians

25. Overcoming Barriers With Education Collaborative Model of Care

26. Case Challenges!

27. Challenge for Diabetes Educators Balancing the Art and Science of DSMES

28. The Diabetes Educator's Role in Improving Insulin Utilization and Outcomes

29. Case Vignette: Part 1

30. Faculty Discussion

31. Faculty Discussion (cont)

32. Faculty Discussion (cont)

33. Case Vignette: Part 2

34. Faculty Discussion

35. Case Vignette: Part 3

36. Faculty Discussion

37. Abbreviations

38. Abbreviations (cont)